Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and

You are here:  Home >>  News >>  Market News >>  Norgine launches Shield’s Feraccru in the UK

Norgine launches Shield’s Feraccru in the UK

December 07, 2018 By pharmatimes

Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year.

Feraccru is a novel, stable, non-salt, oral formulation of ferric iron, which has a differentiated mechanism of action compared to salt-based oral iron therapies, formulated to treat iron deficiency in adults.

"We believe that Feraccru is an important treatment advance for those patients who have iron deficiency, including those suffering from inflammatory bowel disease, and we look forward to helping patients in need in the UK,” noted Andy Crichton, general manager of Norgine UK & Ireland.

Feraccru was recently accepted for review by the US Food and Drug Administration (FDA), just over a month after Norgine signed a deal with Shield allowing it to commercialise the iron deficiency therapy in Europe, Australia and New Zealand.


Editor's Note:

To apply for becoming a contributor of,

welcome to send your CV and sample works to us,


Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
live chat